OPT Opthea Ltd

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2023

Commission File No. 001-39621

 

OPTHEA LIMITED

(Translation of registrant’s name into English)

 

Level 4

650 Chapel Street

South Yarra, Victoria, 3141

Australia

(Address of registrant’s principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

 

 

 

 

 

 

---

 

EXHIBIT INDEX

 

Exhibit		Description
99.1		Press Release: Opthea to Present at the Jefferies 2023 London Healthcare Conference

 

 

---

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

 

	OPTHEA LIMITED
	(Registrant)
	By:	/s/ Frederic Guerard
	Name:	Frederic Guerard
	Title:	Chief Executive Officer

 

Date: 11/09/2023

 

---

Exhibit 99.1

 

 

ASX, Nasdaq and Media Release

November 9, 2023

 

Opthea to Present at the Jefferies 2023 London Healthcare Conference

 

Melbourne, Australia; November 9, 2023 – Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company’s Founder and Chief Innovation Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference being held on November 14th-16th, 2023.

 

Dr. Baldwin’s fireside chat with Jefferies Analyst, Kelly Shi, will occur on Wednesday, November 15th at 12:20PM – 12:55 PM GMT (11:20 PM November 15th AEDT), which can be accessed live by registering at: https://wsw.com/webcast/jeff287/opt/1727508. An archive of the presentation may be accessed for 90 days on the Investors page of the Opthea website at https://ir.opthea.com/events-presentations.

 

 

 

---

 

 

About Opthea Limited

 

Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate OPT-302 is in pivotal Phase 3 clinical trials and being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting VEGF-A alone.

 

Inherent risks of Investment in Biotechnology Companies

 

There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in companies specializing in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments.

 

 

 

Authorized for release to ASX by Megan Baldwin, CEO & Managing Director

 

Company & Media Enquiries:	Join our email database to receive program updates:
U.S.A. & International: Peter Lang, CFO Opthea Limited Tel: +1 917 445-4174   Australia: Rudi Michelson Monsoon Communications Tel: +61 (0) 3 9620 3333   Media: Hershel Berry Blueprint Life Science Group Tel: +1 415 505 3749 hberry@bplifescience.com	Tel: +61 (0) 3 9826 0399 Email: info@opthea.com Web: www.opthea.com

 

 

 

---

---